Ghazaleh Sadri-Vakili. Mass General Research Institute via Twitter

Mass Gen­er­al team presents mouse da­ta to back the case for us­ing re­for­mu­lat­ed asth­ma drug to treat ALS

Can a re­for­mu­la­tion of an old drug on the mar­ket for asth­ma, al­ler­gy and mas­to­cy­to­sis pro­tect against liv­er dis­ease, Alzheimer’s, and amy­otroph­ic lat­er­al scle­ro­sis?

A team from Mass­a­chu­setts Gen­er­al Hos­pi­tal is mak­ing a case for the lat­ter two. Hav­ing re­cent­ly found an in­jec­tion of cro­molyn sodi­um ef­fec­tive in in­hibit­ing amy­loid be­ta (Aβ) ag­gre­ga­tion in vit­ro and in mouse mod­els, re­searchers set out to in­ves­ti­gate whether the same com­pound can achieve the same in ALS.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.